Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB25FCMXY
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,835
Award facts
- Contract value 100% obligated
- $14,834.79 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $14,834.79 by the Defense Logistics Agency (DLA) on August 14, 2025, for the supply of Entyvio 300 mg vials. The contract, which carries no set-aside designation, is scheduled for ultimate completion by September 5, 2025, with performance taking place at the vendor's Park Ridge location. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500 million single-award vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting military health facilities worldwide.
Entyvio is a biologic medication used to treat inflammatory bowel conditions, and this delivery order represents a specific pharmaceutical supply requirement within the DLA's broader medical supply chain operations. DMS Pharmaceutical Group has established itself as a critical supplier to the federal pharmaceutical supply network through consistent contract awards with the DLA, demonstrating capability in distributing branded and generic prescription drugs, biologics, and specialized medical consumables to Department of Defense healthcare sites. The company's status as a woman-owned small business and its established SAM.gov registration since 2001 position it competitively within federal procurement markets for pharmaceutical distribution services.
Quick answers
Who was awarded contract SPE2DB25FCMXY?
SPE2DB25FCMXY was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 14, 2025.
How much is contract SPE2DB25FCMXY worth?
The government has obligated $14,835 on SPE2DB25FCMXY.
Is contract SPE2DB25FCMXY an order under another contract?
Yes. SPE2DB25FCMXY is a delivery order under SPE2DB24D9144, an indefinite delivery contract.
Was contract SPE2DB25FCMXY competed?
The extent of competition for SPE2DB25FCMXY was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award